Clinical Trials Logo
  1. Home
  2. Glioma
  3. NCT05672082
  4. Details
NCT05672082 Clinical Trial

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Glioma Clinical Trial

— INFLAGLI  

Official title:
Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma, a Pilot Study

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT05672082
Other study ID # 2022-1-58-002
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date April 1, 2025

Study information
Verified date February 2024
Source Center Eugene Marquis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are [18F]DPA-714 and 18F-GE180. We hypothesize that [18F]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date April 1, 2025
Est. primary completion date March 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age greater than or equal to 18 years - Suspicion of an operable diffuse glioma - Written informed consent (signed) - Affiliated or beneficiary of a social security plan Exclusion Criteria: - Suspicion of grade I glioma - Surgical urgency (less than 8 days between the suspected diagnosis and surgery) - Pregnant or breastfeeding woman - Persons deprived of liberty or under guardianship - Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• [18F]DPA-714
Participant received one injection of 200 MBq of [18F]DPA-714

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Center Eugene Marquis

Outcome
Type Measure Description Time frame Safety issue
Primary Diagnostic performances of [18F]DPA-714 PET for glioma grading obtained by stereotactic biopsies of glioma Sensitivity and specificity of [18F]DPA-714 PET using anatomopathological assessment of biopsies as gold standard [18F]DPA-714 PET performed up to 30 days before brain surgery
Secondary Comparison of [18F]DPA-714 PET quantitative parameters with anatomopathological assessment of the surgery specimen Comparison of [18F]DPA-714 PET quantitative parameters with the histological types of gliomas, with the IDH1-mutational status, and the 1p19q codeletion status [18F]DPA-714 PET performed up to 30 days before brain surgery
Secondary Comparison of [18F]DPA-714 PET quantitative parameters with tumor microenvironment Comparison of [18F]DPA-714 PET quantitative parameters with the frequency and phenotype of tumor microenvironment different glioma-associated cells [18F]DPA-714 PET performed up to 30 days before brain surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04539574 - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors N/A
Enrolling by invitation NCT04461002 - Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Completed NCT03242824 - The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma Phase 2
Recruiting NCT04186832 - Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy N/A
Completed NCT00424554 - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) Phase 2
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT02805179 - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma Phase 2
Terminated NCT04556929 - Enhanced Detection in Glioma Excision N/A
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Recruiting NCT06043232 - MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Not yet recruiting NCT06043765 - Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training N/A
Not yet recruiting NCT05025969 - Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Completed NCT02978261 - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas Phase 1
Completed NCT01836536 - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients N/A
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Completed NCT01479686 - iMRI Guided Resection in Cerebral Glioma Surgery Phase 3
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A